The vaccinia virus is the "live virus" used in the smallpox vaccine. It is a "pox"-type virus related to smallpox. When given to humans as a vaccine, it helps the body to develop immunity to smallpox. The smallpox vaccine does not contain the smallpox virus and it cannot cause smallpox.
Researchers demonstrate that T helper 1 effector memory cluster of differentiation 4 T cells provide immunity against poxviruses
In a recent study published in the npj vaccines journal, researchers assessed the immune protection elicited by messenger ribonucleic acid (mRNA) vaccines delivering Hepatitis C virus (HCV) E1 and modified E2.
In a recent article published in the United States (U.S.) Centers for Disease Control and Prevention's (CDC) Morbidity and Mortality Weekly Report, a team of researchers discussed the medical countermeasures and clinical considerations for treating severe manifestations of Mpox.
In a recent study posted to the bioRxiv* preprint server, researchers identified a novel antiviral pathway different from the interferon (IFN) pathway that inhibited poxvirus(es) replication.
In new research, researchers demonstrated that individuals recovering from mpox virus (MPXV) infection have neutralizing antibodies that target MPXV antigens A35R and H3L.
In a recent study posted to the medRxiv* preprint server, researchers in the United Kingdom developed a pooled enzyme-linked immunosorbent (ELISA) assay using mpox (MPX) virus (MPXV) antigens and vaccinia virus (VACV) antigens. They also assessed humoral responses to and identification of antigens of MPXV IIa clade and IIb clade, in comparison to recipients of smallpox vaccines (ACAM2000 and IMVANEX).
In a recent study published in the journal Nature Neuroscience, researchers in Spain described the effectiveness of a modified vaccinia virus Ankara (MVA) vector severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine candidate in protecting against SARS-CoV-2 infection in the brain using a mouse model.
Researchers described a messenger ribonucleic acid (mRNA)-lipid nanoparticle monkeypox vaccine encoding four conserved monkeypox virus surface proteins which induced monkeypox virus-specific immunity and elicited heterologous protection when challenged with lethal vaccinia virus.
Scientists have recently estimated and compared anti-mpox and anti-vaccinia antibodies in gay men and the general population.
A new Eurosurveillance study investigated the efficacy of the MVA-BN vaccine, which was administered to individuals after exposure to the virus.
Researchers construct a recombinant host-range restricted vaccinia virus Ankara (rMVAs) expressing the spike proteins of several SARS-CoV-2 variants.
Researchers developed an mRNA technology-based vaccine candidate against the monkeypox virus and evaluated its immunogenicity in animal models.
In a new study, researchers developed two monkeypox (MPX) virus (MPXV) quadrivalent messenger ribonucleic acid (mRNA) vaccines, mRNA-A-lipid nanoparticle (LNP) and mRNA-B-LNP.
In a recent study posted to the bioRxiv* preprint server, researchers in China demonstrated the efficacy of three messenger ribonucleic acid (mRNA) technology-based Monkeypox virus (MPXV) vaccines in combating a lethal Vaccinia virus (VACV) challenge in mice models.
In a recent study posted to the bioRxiv* preprint server, researchers evaluated responses of natural killer (NK) lymphocytes to VACV (vaccinia virus) infections in vivo.
Following ELRIG 2022, News-Medical speaks with Cancer Research Horizons, the innovation engine of Cancer Research UK about their efforts to advance the drug discovery sector.
A recent study presents the first known case of myocarditis as a complication of monkeypox virus infection.
A new study aimed to analyze the kinetics of the pox-specific T-cell induction, the inflammatory profile, and the inflammatory profile in human cases of the current monkeypox outbreak.
Monkeypox has infected more than 77,000 people in more than 100 countries worldwide, and -; similar to COVID-19 -; mutations have enabled the virus to grow stronger and smarter, evading antiviral drugs and vaccines in its mission to infect more people.
Researchers demonstrated how interferon-stimulated gene 15 (ISG15) is involved in the Vaccinia virus (VACV) dissemination.